Table 2. KD-MAS treatment: systematic review [12] and Korean study [5]

Variables	Systematic review [n = 69 (%)]	Korean study [n = 23 (%)]
IVIG and aspirin	69 (100)	23 (100)
Systemic steroids	60 (87)	23 (100)
Cyclosporine	34 (49)	17 (74)
Etoposide	27 (39)	16 (70)
Biologics (anti-TNF, IL-1, or IL-6)	7 (10)	1 (4)
HLH-2004 protocol1)	24 (35)	15 (65)

The HLH-2004 protocol consists of 40 weeks of combination chemotherapy including etoposide and cyclosporine.
KD-MAS: Kawasaki disease complicated with macrophage activation syndrome; IVIG: intravenous immunoglobulin; TNF: tumor necrosis factor; IL: interleukin; HLH: hemophagocytic lymphohistiocytosis.